Contraindicated groups of Valganciclovir and precautions before use

Valganciclovir (Valganciclovir) is a broad-spectrum antiviral drug mainly used to prevent and treat cytomegalovirus (CMV) infection. It is especially widely used in organ transplant patients and people with low immune function. Although it is effective, not all patients are suitable for it. Understanding the contraindications of Vancevir and the precautions before use is crucial to ensure medication safety, avoid serious adverse events, and achieve the best therapeutic effect.

First of all, the contraindications for Vancevir mainly include patients who are allergic to valganciclovir or cyclovir components. Anaphylaxis may manifest as rash, itching, difficulty breathing, or anaphylactic shock, and can be life-threatening if it occurs. Therefore, patients with a history of drug allergy must inform their doctor before taking the drug and perform a drug skin test or choose an alternative if necessary. In addition, pregnant and lactating women should use it with caution. Animal experiments show that valganciclovir may have toxic effects on embryos, and use during pregnancy may increase the risk of abnormal fetal development. If medication is indeed necessary, it must be strictly evaluated by a professional doctor on the risks and benefits before use, and strict contraceptive measures must be taken.

Secondly, patients with severe renal insufficiency or renal failure are also high-risk contraindications for Vancevi. Valganciclovir is mainly excreted through the kidneys. Abnormal renal function can lead to accumulation of the drug in the body, increasing the risk of blood toxicity and adverse reactions, such as neutropenia, thrombocytopenia, or liver function damage. Therefore, it is necessary to evaluate serum creatinine, glomerular filtration rate (eGFR) and urine indicators before use, and adjust the dose or extend the dosing interval according to renal function. Use in patients with acute kidney injury is not recommended unless under strict supervision.

Third, patients with significant bone marrow suppression also need to be cautious. Vancevi may cause a decrease in neutrophils, platelets and red blood cells. Patients with low bone marrow function are more likely to develop infection, bleeding or anemia after taking the drug. Therefore, a comprehensive blood routine examination should be performed before medication to clarify the patient's basic blood indicators, such as neutrophil count, platelets, and hemoglobin levels. If there is severe cytopenia, the medication should be postponed or an alternative plan should be adopted. At the same time, changes in blood routine should be closely monitored during the medication period, and supportive treatment should be given if necessary.

Before taking medication, patients also need to evaluate liver function and previous medication history. Although valganciclovir has relatively low toxicity to the liver, patients with abnormal liver function still need to monitor liver enzyme indicators to avoid aggravating liver damage. In addition, it is necessary to determine whether the patient is concurrently taking other nephrotoxic or myelosuppressive drugs, such as aminoglycoside antibiotics, nonsteroidal anti-inflammatory drugs, or chemotherapy drugs. These drugs may increase the risk of adverse reactions of Vancevir. Before taking medication, the doctor will formulate an individualized plan based on the patient's past medication, disease status and laboratory indicators to ensure medication safety.

In addition, patients should fully understand the usage and potential adverse reactions of the drug before taking Vancevi, take the drug as directed by the doctor, and maintain good living habits, including adequate rest, a balanced diet, and avoiding exposure to infection. Patients with organ transplantation or immunocompromised patients need to strictly abide by the follow-up plan and regularly review blood routine, kidney and liver function, and viral load in order to adjust the dosage or deal with abnormal reactions in a timely manner. Patients should communicate with medical staff in detail before taking medication, including pregnancy, lactation, allergic history and chronic diseases, to ensure that the medication is used under safe conditions.

To sum up, the contraindication groups for Vancevir mainly include those with drug allergies, pregnant and lactating women, patients with severe renal insufficiency and those with obvious bone marrow suppression. Before medication, a comprehensive assessment of blood, kidney and liver function and previous medication needs to be carried out, and potential adverse reactions must be fully understood. Through standardized pre-medication screening, individualized dose adjustment and regular monitoring, most patients can complete treatment within a safe range, thereby effectively preventing and controlling CMV infection and improving treatment effects.

Reference materials:https://www.drugs.com/